



ESOCAP ANNOUNCES ISSUE OF A PATENT IN RUSSIA FOR ITS SMART APPLICATION TECHNOLOGY FOR THE UPPER GASTROINTESTINAL TRACT

Basel, Switzerland, March 12, 2020

EsoCap AG announced today that the Russia Patent and Trademark Office issued a patent under number 2714882 on February 20, 2020, based on patent application no. 2017132866/04 (057778). The patent is directed at the smart application technology enabling effective topical treatment of several diseases of the esophagus. EsoCap AG is pursuing similar patent applications in other regions and countries, including the USA, Europe, Japan and other strategic countries.

"Issue of the Russian patent confirms the highly innovative character of EsoCap's technology", commented Isabelle Racamier, EsoCap AG CEO. "Ensuring a robust intellectual property position around EsoCap technology is an integral part of advancing the program and the claims granted exemplify our technology's innovative character."

Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights to this unique drug delivery technology developed by the University of Greifswald. Up to now, local treatment of diseases of the esophagus was not possible due to the ultra-short transit time of conventional drug formulations. "EsoCap smart application technology is definitely a paradigm shift for effective and safe treatment of esophageal diseases. EsoCap technology will be beneficial in at least six therapeutic indications affecting 370 million patients," said Dr Peter Stangier, Director Strategic Planning at EsoCap AG.

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing the efficient topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contacts:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com